Hypothesis

Berberine’s low-dose activation of lysosomal AMPK drives TFEB-dependent lysosomal biogenesis and autophagic flux, leading to post-translational clearance of PCSK9 protein. This mechanism operates alongside its transcriptional inhibition of PCSK9 and explains the dose- and formulation-dependent inconsistencies observed across models. When combined with metformin, which activates cytosolic AMPK via a PEN2-dependent pathway, the two drugs achieve complementary spatial AMPK signaling (lysosomal vs cytosolic), resulting in synergistic metabolic improvements.

Testable Predictions

• Prediction 1: In HepG2 cells treated with berberine (0.1–2.5 µM), lysosomal AMPK phosphorylation (p-AMPKα-Lys) will increase, accompanied by TFEB nuclear translocation and up-regulation of lysosomal genes (LAMP1, CTSB). siRNA-mediated TFEB knock-down will block berberine-induced reduction of PCSK9 protein without altering PCSK9 mRNA levels.
• Prediction 2: Metformin will increase cytosolic AMPK phosphorylation (p-AMPKα-Cyt) but not lysosomal AMPK or TFEB activation. The combination of berberine + metformin will produce additive increases in both lysosomal and cytosolic p-AMPK, correlating with greater LDLR upregulation and LDL-C clearance.
• Prediction 3: In vivo, high-fat diet mice given berberine will show elevated hepatic autophagic flux (LC3-II/I ratio, p62 degradation) and reduced PCSK9 protein; autophagy inhibition (chloroquine or ATG5 KO) will abolish the PCSK9-lowering effect while preserving mRNA suppression.

Mechanistic Rationale

Berberine’s AXIN1-dependent lysosomal AMPK activation positions it upstream of the mTORC1-TFEB axis. AMPK phosphorylates and inhibits mTORC1, allowing TFEB to translocate to the nucleus and stimulate lysosomal biogenesis. Enhanced lysosomal capacity accelerates the degradation of secreted PCSK9 via the endosomal-lysosomal route, a pathway distinct from transcriptional control. Metformin’s cytosolic AMPK activation improves hepatic insulin signaling and gluconeogenesis but does not significantly affect TFEB. Therefore, the combination yields simultaneous transcriptional (PCSK9 ↓) and post-translational (PCSK9 protein clearance) suppression, accounting for the observed 96% efficacy in T2DM patients versus 82% with metformin alone.

Falsifiability

If TFEB knock-down or lysosomal autophagy inhibition fails to attenuate berberine-mediated PCSK9 protein reduction, or if berberine does not increase lysosomal AMPK/TFEB activity at clinically relevant doses, the hypothesis would be refuted. Similarly, if the combination does not produce additive lysosomal and cytosolic AMPK signals, the proposed spatial synergy would be invalid.

References

• Berberine activates lysosomal AMPK via AXIN1 [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1148611/full]
• Combination therapy efficacy in T2DM [https://journals.sagepub.com/doi/10.1177/09731296241287592]
• Berberine lowers PCSK9 and LDL-C [https://pmc.ncbi.nlm.nih.gov/articles/PMC9650693/]
• Berberine protects podocytes via AMPK/autophagy [https://pubmed.ncbi.nlm.nih.gov/27887947/]
• Ongoing prevention trial [https://clinicaltrials.gov/study/NCT05749874]